# An Open, Single-center, Safety and Efficacy Study of Conbercept in Patients With Very Low Vision Secondary to Wet Age-related Macular Degeneration (wAMD)

> **NCT02098720** · PHASE2 · UNKNOWN · sponsor: **Chengdu Kanghong Biotech Co., Ltd.** · enrollment: 30 (estimated)

## Conditions studied

- Very Low Vision Secondary to Wet Age-related Macular Degeneration

## Interventions

- **DRUG:** Conbercept

## Key facts

- **NCT ID:** NCT02098720
- **Lead sponsor:** Chengdu Kanghong Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-12
- **Primary completion:** 2014-03
- **Final completion:** —
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2014-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02098720

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02098720, "An Open, Single-center, Safety and Efficacy Study of Conbercept in Patients With Very Low Vision Secondary to Wet Age-related Macular Degeneration (wAMD)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02098720. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*